PFCS
LXEO icon

Pale Fire Capital SE’s Lexeo Therapeutics LXEO Stock Holding History

Pale Fire Capital SE’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,302
Closed -$221K – 71
2025
Q4 		$221K Sell
22,302
-11,348
-34% -$104K 0.01% 46
2025
Q3 		$223K Buy
33,650
+6,000
+22% +$29K 0.02% 44
2025
Q2 		$111K Buy
27,650
+8,750
+46% +$28.8K 0.01% 55
2025
Q1 		$65.6K Buy
18,900
+2,800
+17% +$12.4K 0.01% 58
2024
Q4 		$106K Buy
+16,100
New +$127K 0.02% 42

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pale Fire Capital SE's LXEO Position: Q1 2026 in Review

Pale Fire Capital SE sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 22,302 shares — an estimated $221K sold.

Pale Fire Capital SE first reported a position in LXEO in Q4 2024 and held it in 5 quarters. The position peaked at $223K in Q3 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Pale Fire Capital SE reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Pale Fire Capital SE sold 22,302 Lexeo Therapeutics shares in Q1 2026, an estimated $221K.
  • Pale Fire Capital SE first reported a position in Lexeo Therapeutics in Q4 2024 and held it in 5 quarters.
  • Pale Fire Capital SE's Lexeo Therapeutics position peaked at $223K in Q3 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Pale Fire Capital SE's 13F filing for Q1 2026, filed 14 May 2026.